The effects of phage defense on recombinant protein expression

噬菌体防御对重组蛋白表达的影响

• 批准号: 386286-2010
• 负责人: Navarre, William
• 金额: $ 2.77万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2014
• 资助国家: 加拿大
• 起止时间: 2014-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=550360
• 关键词: effects; phage; defense; recombinant; protein

To generate large quantities of proteins used for biotechnology applications, it is usually necessary to express the protein as a "recombinant" product in an organism distinct from the original source (e.g. producing a human protein in a bacterial cell). This is necessary because it is generally difficult to obtain adequate quantities of protein from native sources. When practical, bacterial systems are ideal because bacteria grow rapidly, bacterial growth medium is inexpensive, bacterial physiology is relatively well understood, and several strains of genetically modified bacteria have been developed that can produce high-quality, intact recombinant proteins. Despite the development of techniques for protein production in bacterial systems, it is still difficult to obtain high-yields of certain proteins for unknown reasons. This is particularly true when attempting the production of proteins from higher organisms such as humans, due to the small but significant differences in human gene structure compared to bacteria. In 2000 the sales of the 30 leading recombinant proteins exceeded $13 billion, $5.6 billion of which were produced in E. coli. Advances that make it easier to express or increase yield of recombinant proteins would be of considerable interest to a large number of important industries.

为了产生用于生物技术应用的大量蛋白质，通常有必要在与原始源不同的生物体中表达蛋白质为“重组”产物（例如，在细菌细胞中产生人类蛋白质）。 这是必要的，因为通常很难从天然来源获得足够的蛋白质。 当实用的细菌系统是理想的，因为细菌生长迅速，细菌生长培养基廉价，细菌性生理学相对良好，并且已经开发出几种遗传改性细菌菌株，可以产生高质量的完整重组蛋白。 尽管开发了细菌系统中蛋白质生产的技术，但由于未知原因，仍然很难获得某些蛋白质的高收益。 当尝试从人类基因结构的较小但显着的差异与细菌相比，尝试从较高的生物（例如人类）的蛋白质产生蛋白质时尤其如此。 2000年，30个领先的重组蛋白的销售额超过130亿美元，其中56亿美元在大肠杆菌中生产。 使大量重要行业更容易表达或提高重组蛋白产量的进步将引起相当大的兴趣。